Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2025

This “Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2025” report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in Bronchiolitis Obliterans Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Bronchiolitis Obliterans Syndrome: Understanding

Bronchiolitis Obliterans Syndrome: Overview

Bronchiolitis obliterans is also known as obliterative bronchiolitis or constrictive bronchiolitis. When it occurs after lung transplantation or hematopoietic stem cell transplantation (HSCT), it is called bronchiolitis obliterans syndrome. Bronchiolitis obliterans is a type of obstructive lung disease of the small airways. It is a rare disease with characteristic features of fibrosis of terminal and distal bronchioles and spirometry showing airflow obstruction. It usually leads to a progressive decline in lung function and has variable outcomes.

Bronchiolitis obliterans can develop due to a variety of risk factors. It is one of the most common noninfectious complications after lung transplant and hematopoietic stem cell transplantation. Other etiologies include exposure to inhaled toxins and gases, such as sulfur mustard gas, nitrogen oxides, diacetyl (used as popcorn flavoring), fly ash, and fiberglass. Bronchiolitis obliterans is also associated with autoimmune disorders, especially rheumatoid arthritis, systemic lupus erythematosus (SLE), and less commonly with inflammatory bowel disease. It is known to occur after a respiratory viral infection, particularly adenovirus and respiratory syncytial virus, especially in children. Other infections associated with bronchiolitis obliterans are HIV, mycoplasma, bacteria, fungi, and Human Herpes Virus (HHV) 8. Rare conditions like Castleman disease and paraneoplastic pemphigus have also been linked to bronchiolitis obliterans. Other associations include microcarcinoid tumorlets and cryptogenic constrictive bronchiolitis.

The most common symptoms of bronchiolitis obliterans include a dry cough, shortness of breath, wheezing, and feeling tired. These symptoms generally start gradually and worsen over weeks to months. Patients often experience exercise intolerance and may feel extremely short of breath and exhausted after moderate physical exertion. The symptoms are usually persistent and unrelated to factors such as weather, unlike asthma. In some cases, symptoms can occur suddenly. Bronchiolitis obliterans can also cause other associated symptoms depending on the underlying cause, such as a skin rash due to toxin exposure or complications from chemotherapy following a lung or bone marrow transplant.

The treatment of bronchiolitis obliterans syndrome (BOS) after lung transplantation involves a combination of therapies. First-line treatment includes systemic corticosteroids, calcineurin inhibitors (cyclosporine or tacrolimus), and azithromycin. Other therapies that may be used include extracorporeal photopheresis, montelukast, and re-transplantation in selected cases. Prompt treatment of complications, such as infections, is also important in managing patients with BOS.

'Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bronchiolitis Obliterans Syndrome pipeline landscape is provided which includes the disease overview and Bronchiolitis Obliterans Syndrome treatment guidelines. The assessment part of the report embraces, in depth Bronchiolitis Obliterans Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bronchiolitis Obliterans Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Bronchiolitis Obliterans Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Bronchiolitis Obliterans Syndrome.

Bronchiolitis Obliterans Syndrome Emerging Drugs Chapters

This segment of the Bronchiolitis Obliterans Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bronchiolitis Obliterans Syndrome Emerging Drugs

Liposomal Cyclosporine A: Zambon

Liposomal Cyclosporine A for Inhalation (LCsAi) is a novel liposomal formulation of cyclosporine A developed for inhaled delivery to the lungs. Calcineurin inhibitors (CNIs), like cyclosporine A, are highly potent immunosuppressive drugs and a cornerstone of lung transplant medicine. LCsAi is administered via a drug-specific investigational eFlow technology nebulizer system (PARI Pharma GmbH). The investigational drug-device combination is designed to deliver LCsAi to the site of disease in the lung. LCsAi received orphan drug designation for the treatment of BOS from the US Food and Drug Administration and European Medicines Agency. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Bronchiolitis Obliterans Syndrome.

Bronchiolitis Obliterans Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Bronchiolitis Obliterans Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Bronchiolitis Obliterans Syndrome

There are approx. 6+ key companies which are developing the therapies for Bronchiolitis Obliterans Syndrome. The companies which have their Bronchiolitis Obliterans Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Zambon.

Phases

The report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Bronchiolitis Obliterans Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bronchiolitis Obliterans Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bronchiolitis Obliterans Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchiolitis Obliterans Syndrome drugs.

Bronchiolitis Obliterans Syndrome Report Insights

• Bronchiolitis Obliterans Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bronchiolitis Obliterans Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Bronchiolitis Obliterans Syndrome drugs?
• How many Bronchiolitis Obliterans Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bronchiolitis Obliterans Syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bronchiolitis Obliterans Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bronchiolitis Obliterans Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Breath Therapeutics
• SCM Lifescience
• OrphAI Therapeutics

Key Products

• Liposomal Cyclosporine A
• SCM-CGH
• LAM-001

This product will be delivered within 2 business days.